NeuroSearch gains on obesity data

NeuroSearch (CSE:NEUR) gained DKK34.5 (15%) to DKK258 on Tuesday after reporting 24-week data from the Phase II TIPO-4 trial of tesofensine to treat obesity. All 140 patients in the open-label, 48-week extension of the double-blind, placebo-controlled Phase II TIPO-1 trial received 0.5 mg of the triple monoamine reuptake inhibitor. Patients who had previously received placebo in TIPO-1 lost about 9 kg in TIPO-4, and those who had received 0.5 mg of tesofensine in TIPO-1 lost about 4 kg in TIPO-4. Data from TIPO-4 patients who received 0.25 or 1 mg of tesofensine in TIPO-1 were not provided. Final data from the extension study will be reported by year end. ...